Profile change history

What changed for Pasireotide?

A deterministic history of records added to PeptideScanner and preserved profile or record revisions connected through the reviewed Pasireotide identity.

63Total events
63Record additions
0Version changes
15Cited source years

Collection chronology

Evidence added to PeptideScanner

Browse all 63 connected records →

Showing the latest 63 additions by PeptideScanner publication date; the complete connected record set remains available on the cross-source timeline. Most recent addition: November 15, 2026.

Record added

ClinicalTrials.gov record NCT00171730

PeptideScanner retained ClinicalTrials.gov record NCT00171730 at 2026-11-15T22:05:38.400Z. Its registry update date was 2021-09-05, and PeptideScanner's reviewed identity mapping was pasireotide.

PeptideScanner change date
November 15, 2026
Cited source date
September 5, 2021
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00171951

PeptideScanner retained ClinicalTrials.gov record NCT00171951 at 2026-11-15T22:05:38.400Z. Its registry update date was 2021-06-02, and PeptideScanner's reviewed identity mapping was pasireotide.

PeptideScanner change date
November 15, 2026
Cited source date
June 2, 2021
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00434148

PeptideScanner retained ClinicalTrials.gov record NCT00434148 at 2026-11-15T22:05:38.400Z. Its registry update date was 2016-03-08, and PeptideScanner's reviewed identity mapping was pasireotide.

PeptideScanner change date
November 15, 2026
Cited source date
March 8, 2016
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00446082

PeptideScanner retained ClinicalTrials.gov record NCT00446082 at 2026-11-15T22:05:38.400Z. Its registry update date was 2020-12-21, and PeptideScanner's reviewed identity mapping was pasireotide.

PeptideScanner change date
November 15, 2026
Cited source date
December 21, 2020
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00698464

PeptideScanner retained ClinicalTrials.gov record NCT00698464 at 2026-11-15T22:05:38.400Z. Its registry update date was 2020-12-21, and PeptideScanner's reviewed identity mapping was pasireotide.

PeptideScanner change date
November 15, 2026
Cited source date
December 21, 2020
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00804336

PeptideScanner retained ClinicalTrials.gov record NCT00804336 at 2026-11-15T22:05:38.400Z. Its registry update date was 2016-10-19, and PeptideScanner's reviewed identity mapping was pasireotide.

PeptideScanner change date
November 15, 2026
Cited source date
October 19, 2016
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT01128192

PeptideScanner retained ClinicalTrials.gov record NCT01128192 at 2026-11-15T22:05:38.400Z. Its registry update date was 2014-12-25, and PeptideScanner's reviewed identity mapping was pasireotide.

PeptideScanner change date
November 15, 2026
Cited source date
December 25, 2014
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT01137682

PeptideScanner retained ClinicalTrials.gov record NCT01137682 at 2026-11-15T22:05:38.400Z. Its registry update date was 2018-04-05, and PeptideScanner's reviewed identity mapping was pasireotide.

PeptideScanner change date
November 15, 2026
Cited source date
April 5, 2018
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT01270321

PeptideScanner retained ClinicalTrials.gov record NCT01270321 at 2026-11-15T22:05:38.400Z. Its registry update date was 2021-02-17, and PeptideScanner's reviewed identity mapping was pasireotide.

PeptideScanner change date
November 15, 2026
Cited source date
February 17, 2021
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT01356862

PeptideScanner retained ClinicalTrials.gov record NCT01356862 at 2026-11-15T22:05:38.400Z. Its registry update date was 2017-01-25, and PeptideScanner's reviewed identity mapping was pasireotide.

PeptideScanner change date
November 15, 2026
Cited source date
January 25, 2017
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT01385956

PeptideScanner retained ClinicalTrials.gov record NCT01385956 at 2026-11-15T22:05:38.400Z. Its registry update date was 2020-09-28, and PeptideScanner's reviewed identity mapping was pasireotide.

PeptideScanner change date
November 15, 2026
Cited source date
September 28, 2020
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT01468532

PeptideScanner retained ClinicalTrials.gov record NCT01468532 at 2026-11-15T22:05:38.400Z. Its registry update date was 2021-03-25, and PeptideScanner's reviewed identity mapping was pasireotide.

PeptideScanner change date
November 15, 2026
Cited source date
March 25, 2021
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT01469572

PeptideScanner retained ClinicalTrials.gov record NCT01469572 at 2026-11-15T22:05:38.400Z. Its registry update date was 2018-10-18, and PeptideScanner's reviewed identity mapping was pasireotide.

PeptideScanner change date
November 15, 2026
Cited source date
October 18, 2018
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT01488487

PeptideScanner retained ClinicalTrials.gov record NCT01488487 at 2026-11-15T22:05:38.400Z. Its registry update date was 2016-04-07, and PeptideScanner's reviewed identity mapping was pasireotide.

PeptideScanner change date
November 15, 2026
Cited source date
April 7, 2016
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT01620138

PeptideScanner retained ClinicalTrials.gov record NCT01620138 at 2026-11-15T22:05:38.400Z. Its registry update date was 2016-08-22, and PeptideScanner's reviewed identity mapping was pasireotide.

PeptideScanner change date
November 15, 2026
Cited source date
August 22, 2016
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT01637272

PeptideScanner retained ClinicalTrials.gov record NCT01637272 at 2026-11-15T22:05:38.400Z. Its registry update date was 2017-05-10, and PeptideScanner's reviewed identity mapping was pasireotide.

PeptideScanner change date
November 15, 2026
Cited source date
May 10, 2017
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT01794793

PeptideScanner retained ClinicalTrials.gov record NCT01794793 at 2026-11-15T22:05:38.400Z. Its registry update date was 2024-10-01, and PeptideScanner's reviewed identity mapping was pasireotide.

PeptideScanner change date
November 15, 2026
Cited source date
October 1, 2024
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT01895296

PeptideScanner retained ClinicalTrials.gov record NCT01895296 at 2026-11-15T22:05:38.400Z. Its registry update date was 2013-07-10, and PeptideScanner's reviewed identity mapping was pasireotide.

PeptideScanner change date
November 15, 2026
Cited source date
July 10, 2013
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT02021942

PeptideScanner retained ClinicalTrials.gov record NCT02021942 at 2026-11-15T22:05:38.400Z. Its registry update date was 2018-02-05, and PeptideScanner's reviewed identity mapping was pasireotide.

PeptideScanner change date
November 15, 2026
Cited source date
February 5, 2018
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT02215070

PeptideScanner retained ClinicalTrials.gov record NCT02215070 at 2026-11-15T22:05:38.400Z. Its registry update date was 2021-11-17, and PeptideScanner's reviewed identity mapping was pasireotide.

PeptideScanner change date
November 15, 2026
Cited source date
November 17, 2021
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT02310269

PeptideScanner retained ClinicalTrials.gov record NCT02310269 at 2026-11-15T22:05:38.400Z. Its registry update date was 2024-10-15, and PeptideScanner's reviewed identity mapping was pasireotide.

PeptideScanner change date
November 15, 2026
Cited source date
October 15, 2024
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT02527993

PeptideScanner retained ClinicalTrials.gov record NCT02527993 at 2026-11-15T22:05:38.400Z. Its registry update date was 2018-03-07, and PeptideScanner's reviewed identity mapping was pasireotide.

PeptideScanner change date
November 15, 2026
Cited source date
March 7, 2018
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT02622906

PeptideScanner retained ClinicalTrials.gov record NCT02622906 at 2026-11-15T22:05:38.400Z. Its registry update date was 2015-12-07, and PeptideScanner's reviewed identity mapping was pasireotide.

PeptideScanner change date
November 15, 2026
Cited source date
December 7, 2015
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT02713776

PeptideScanner retained ClinicalTrials.gov record NCT02713776 at 2026-11-15T22:05:38.400Z. Its registry update date was 2025-12-19, and PeptideScanner's reviewed identity mapping was pasireotide.

PeptideScanner change date
November 15, 2026
Cited source date
December 19, 2025
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT02775227

PeptideScanner retained ClinicalTrials.gov record NCT02775227 at 2026-11-15T22:05:38.400Z. Its registry update date was 2020-08-24, and PeptideScanner's reviewed identity mapping was pasireotide.

PeptideScanner change date
November 15, 2026
Cited source date
August 24, 2020
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT03103009

PeptideScanner retained ClinicalTrials.gov record NCT03103009 at 2026-11-15T22:05:38.400Z. Its registry update date was 2021-09-29, and PeptideScanner's reviewed identity mapping was pasireotide.

PeptideScanner change date
November 15, 2026
Cited source date
September 29, 2021
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT03847207

PeptideScanner retained ClinicalTrials.gov record NCT03847207 at 2026-11-15T22:05:38.400Z. Its registry update date was 2025-02-19, and PeptideScanner's reviewed identity mapping was pasireotide.

PeptideScanner change date
November 15, 2026
Cited source date
February 19, 2025
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT05928390

PeptideScanner retained ClinicalTrials.gov record NCT05928390 at 2026-11-15T22:05:38.400Z. Its registry update date was 2026-09-17, and PeptideScanner's reviewed identity mapping was pasireotide.

PeptideScanner change date
November 15, 2026
Cited source date
September 17, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT06295952

PeptideScanner retained ClinicalTrials.gov record NCT06295952 at 2026-11-15T22:05:38.400Z. Its registry update date was 2026-03-04, and PeptideScanner's reviewed identity mapping was pasireotide.

PeptideScanner change date
November 15, 2026
Cited source date
March 4, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT06456359

PeptideScanner retained ClinicalTrials.gov record NCT06456359 at 2026-11-15T22:05:38.400Z. Its registry update date was 2025-01-13, and PeptideScanner's reviewed identity mapping was pasireotide.

PeptideScanner change date
November 15, 2026
Cited source date
January 13, 2025
Evidence lane
Clinical trials
Record added

Federal Register notice 2012-25483

The Federal Register published notice 2012-25483, attributed to FDA and its parent HHS department, on 2012-10-17. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Pasireotide.

PeptideScanner change date
November 15, 2026
Cited source date
October 17, 2012
Evidence lane
Regulatory
Record added

Federal Register notice 2015-10994

The Federal Register published notice 2015-10994, attributed to FDA and its parent HHS department, on 2015-05-07. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; SIGNIFOR,” and PeptideScanner's exact reviewed identity mapping connects the document to Pasireotide.

PeptideScanner change date
November 15, 2026
Cited source date
May 7, 2015
Evidence lane
Regulatory
Record added

Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial.

PubMed lists PMID 18957506 in The Journal of clinical endocrinology and metabolism as Clinical Trial, Phase II, Journal Article, Multicenter Study, with publication-date metadata of 2008-10-28 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
March 9, 2022
Evidence lane
Literature metadata
Record added

Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease.

PubMed lists PMID 20463350 in The New England journal of medicine as Clinical Trial, Letter, Multicenter Study, with publication-date metadata of 2010-05-13 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
March 15, 2022
Evidence lane
Literature metadata
Record added

Pasireotide for the treatment of Cushing's disease.

PubMed lists PMID 20533892 in Expert opinion on investigational drugs as Journal Article, Review, with publication-date metadata of 2010-07 (month precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
November 20, 2014
Evidence lane
Literature metadata
Record added

Management of hyperglycaemia in Cushing's disease: experts' proposals on the use of pasireotide.

PubMed lists PMID 23228667 in Diabetes & metabolism as Journal Article, Review, with publication-date metadata of 2012-12-08 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
January 28, 2026
Evidence lane
Literature metadata
Record added

Pasireotide: a review of its use in Cushing's disease.

PubMed lists PMID 23605695 in Drugs as Journal Article, Review, with publication-date metadata of 2013-05 (month precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
October 11, 2026
Evidence lane
Literature metadata
Record added

Pasireoride (Signifor) for Cushing's disease.

PubMed lists PMID 23669783 in The Medical letter on drugs and therapeutics as Journal Article, Review, with publication-date metadata of 2013-05-13 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
November 20, 2014
Evidence lane
Literature metadata
Record added

Assessment of the absorption, metabolism and excretion of [¹⁴C]pasireotide in healthy volunteers using accelerator mass spectrometry.

PubMed lists PMID 23680921 in Cancer chemotherapy and pharmacology as Clinical Trial, Phase I, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2013-05-17 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
November 20, 2014
Evidence lane
Literature metadata
Record added

Pasireotide and mifepristone: new options in the medical management of Cushing's disease.

PubMed lists PMID 24126229 in Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists as Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2014-01 (month precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
February 4, 2021
Evidence lane
Literature metadata
Record added

Pasireotide monotherapy in Cushing's disease: a single-centre experience with 5-year extension of phase III Trial.

PubMed lists PMID 24287689 in Pituitary as Case Reports, Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2014-12 (month precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
March 9, 2022
Evidence lane
Literature metadata
Record added

Long-term medical treatment of cushing's disease with pasireotide: a review of current evidence and clinical experience.

PubMed lists PMID 25003365 in Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association as Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2014-07-08 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
September 18, 2014
Evidence lane
Literature metadata
Record added

Everolimus and pasireotide for advanced and metastatic hepatocellular carcinoma.

PubMed lists PMID 25613083 in Investigational new drugs as Clinical Trial, Phase II, Journal Article, Research Support, N.I.H., Extramural, with publication-date metadata of 2015-01-23 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
March 11, 2022
Evidence lane
Literature metadata
Record added

Phase I trial of combination of FOLFIRI and pasireotide, a somatostatin analogue, in advanced gastrointestinal malignancies.

PubMed lists PMID 26275531 in Investigational new drugs as Clinical Trial, Phase I, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2015-08-16 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
February 16, 2021
Evidence lane
Literature metadata
Record added

Pasireotide for the treatment of acromegaly.

PubMed lists PMID 26808354 in Expert opinion on pharmacotherapy as Journal Article, Review, with publication-date metadata of 2016-02-17 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
March 10, 2022
Evidence lane
Literature metadata
Record added

Management of Hyperglycemia in Patients With Acromegaly Treated With Pasireotide LAR.

PubMed lists PMID 27473537 in Drugs as Journal Article, Review, with publication-date metadata of 2016-09 (month precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
January 27, 2026
Evidence lane
Literature metadata
Record added

Insulin sensitivity and secretion and adipokine profile in patients with Cushing's disease treated with pasireotide.

PubMed lists PMID 29396758 in Journal of endocrinological investigation as Journal Article, Randomized Controlled Trial, with publication-date metadata of 2018-02-02 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
January 9, 2019
Evidence lane
Literature metadata
Record added

Phase I Trial of the Combination of Docetaxel, Prednisone, and Pasireotide in Metastatic Castrate-Resistant Prostate Cancer.

PubMed lists PMID 29534939 in Clinical genitourinary cancer as Clinical Trial, Phase I, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, with publication-date metadata of 2018-02-13 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
February 15, 2019
Evidence lane
Literature metadata
Record added

How to Position Pasireotide LAR Treatment in Acromegaly.

PubMed lists PMID 30608534 in The Journal of clinical endocrinology and metabolism as Journal Article, Review, with publication-date metadata of 2019-06-01 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
May 5, 2020
Evidence lane
Literature metadata
Record added

Pansomatostatin Agonist Pasireotide Long-Acting Release for Patients with Autosomal Dominant Polycystic Kidney or Liver Disease with Severe Liver Involvement: A Randomized Clinical Trial.

PubMed lists PMID 32843370 in Clinical journal of the American Society of Nephrology : CJASN as Clinical Trial, Phase II, Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, with publication-date metadata of 2020-08-25 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
August 1, 2024
Evidence lane
Literature metadata
Record added

Pasireotide for Refractory Hypoglycemia in Malignant Insulinoma- Case Report and Review of the Literature.

PubMed lists PMID 35518928 in Frontiers in endocrinology as Case Reports, Review, Journal Article, with publication-date metadata of 2022-04-19 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
November 5, 2023
Evidence lane
Literature metadata
Record added

Pituitary acting drugs: cabergoline and pasireotide.

PubMed lists PMID 35670988 in Pituitary as Journal Article, Review, with publication-date metadata of 2022-06-07 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
October 30, 2026
Evidence lane
Literature metadata
Record added

Second line treatment of acromegaly: Pasireotide or Pegvisomant?

PubMed lists PMID 35931640 in Best practice & research. Clinical endocrinology & metabolism as Meta-Analysis, Journal Article, Review, with publication-date metadata of 2022-07-16 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
December 22, 2022
Evidence lane
Literature metadata
Record added

Predictive factors and the management of hyperglycemia in patients with acromegaly and Cushing's disease receiving pasireotide treatment: post hoc analyses from the SOM230B2219 study.

PubMed lists PMID 38577574 in Frontiers in endocrinology as Clinical Trial, Phase IV, Journal Article, Randomized Controlled Trial, with publication-date metadata of 2024-03-21 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
June 3, 2026
Evidence lane
Literature metadata
Record added

Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs.

PubMed lists PMID 38713182 in Endocrine-related cancer as Journal Article, Multicenter Study, with publication-date metadata of 2024-05-27 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
September 16, 2026
Evidence lane
Literature metadata
Record added

Long-term pasireotide-LAR treatment in the personalized therapy of patients with complex acromegaly: a collection of clinical experiences.

PubMed lists PMID 38817802 in Drugs in context as Journal Article, with publication-date metadata of 2024-05-20 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
June 1, 2024
Evidence lane
Literature metadata
Record added

The Role of the GH Receptor Polymorphisms as a Prognostic Factor of Vertebral Fractures in Acromegalic Patients Resistant to First-generation SSAs and Treated with Pegvisomant or Pasireotide LAR.

PubMed lists PMID 38982703 in Endocrine, metabolic & immune disorders drug targets as Journal Article, with publication-date metadata of 2024-07-05 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
July 10, 2024
Evidence lane
Literature metadata
Record added

Management of Diabetes Mellitus in Acromegaly and Cushing's Disease with Focus on Pasireotide Therapy: A Narrative Review.

PubMed lists PMID 39072348 in Diabetes, metabolic syndrome and obesity : targets and therapy as Journal Article, Review, with publication-date metadata of 2024-07-23 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
July 30, 2024
Evidence lane
Literature metadata
Record added

Rapid Resolution of Recalcitrant Headache With Pasireotide in an Adult Patient With Acromegaly.

PubMed lists PMID 39129819 in JCEM case reports as Case Reports, Journal Article, with publication-date metadata of 2024-08-09 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
August 15, 2024
Evidence lane
Literature metadata
Record added

Real-World Experience with Pasireotide-LAR in Cushing's Disease: Single-Center 12-Month Observational Study.

PubMed lists PMID 40283624 in Journal of clinical medicine as Journal Article, with publication-date metadata of 2025-04-18 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
April 28, 2025
Evidence lane
Literature metadata
Record added

Real-life data on pasireotide in monotherapy or combined in active Cushing's disease.

PubMed lists PMID 41323967 in Frontiers in endocrinology as Journal Article, with publication-date metadata of 2025-11-13 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
December 3, 2025
Evidence lane
Literature metadata
Record added

Pasireotide-LAR and pegvisomant combination in resistant acromegaly: a case series of predominantly mammosomatotroph adenomas.

PubMed lists PMID 42778805 in Pituitary as Journal Article, with publication-date metadata of 2026-09-23 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
October 31, 2026
Evidence lane
Literature metadata